General form of registration statement for all companies including face-amount certificate companies

Condensed Consolidated Statements of Cash Flows

v3.21.4
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Cash Flows From Operating Activities        
Net loss $ (11,214) $ (18,308) $ (26,451) $ (26,740)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization 4,350 4,102 5,501 4,524
Interest accretion 375 414 549 440
Reversal of 2019 bonus accrual (1,156) (1,156)
Bad debt expense (140) 250 585 499
Mark to market on warrants 137 (62) (61) (279)
Stock-based compensation 1,228 1,354 2,187 1,535
Amortization of deferred financing fees 110    
Accrued interest - Related Parties 372    
ESPP expense 86 27 55
Change in fair value of contingent consideration (57) (489) (44)
Deferred income taxes     37 18
Change in estimate on collectability of accounts receivable     3,479
Asset impairment     37
Gain on DiamiR transaction (235)    
Other gains and expenses, net (2) 18
Other changes in operating assets and liabilities:        
Decrease (increase) in accounts receivable 1,788 1,625 1,725 (1,102)
Decrease in other current assets (413) (898) 241 129
Increase in other long-term assets (14) (11)
Decrease in accounts payable (2,084) (1,319) (198) (938)
Increase in accrued salaries and bonus (433) 129 1,976 362
Increase (decrease) in accrued liabilities (1,349) 1,472 1,395 (1,301)
Increase in long-term liabilities (6) (25) 88 454
Net cash used in operating activities (7,501) (12,395) (13,979) (18,957)
Cash Flows From Investing Activity        
Purchase of property and equipment (192) (1,275) (1,575) (131)
Acquisition of Biopharma, net of cash acquired     (13,829)
Sale of property and equipment 39 13
Net cash used in investing activities (153) (1,275) (1,575) (13,947)
Cash Flows From Financing Activities        
Issuance of common stock, net of expenses 335 434 434 6,478
Issuance of Series B preferred stock, net of expenses 19,223 19,223
Issuance of preferred stock, net of expenses     25,744
Payment of CGIX note and related interest     (6,024)
Loan proceeds - related parties 7,500    
Deferred financing fees (123)    
Payments on line of credit (3,000)    
(Payments) borrowings on Line of Credit     (3,000) 3,000
Cash paid for repurchase of restricted shares     (52) (41)
Net cash provided by financing activities 7,712 16,657 16,605 29,157
Net increase (decrease) in cash, cash equivalents and restricted cash 58 2,987 1,051 (3,747)
Cash, cash equivalents and restricted cash – beginning 3,372 2,321 2,321 6,068
Cash, cash equivalents and restricted cash – ending $ 3,430 $ 5,308 $ 3,372 $ 2,321